Fig. 8: JAB1 is overexpressed in various cancer types and serves as a prospective cancer biomarker.
From: JAB1/CRL4B complex represses PPARG/ACSL5 expression to promote breast tumorigenesis
A, B Immunohistochemical staining and expression analysis of JAB1, CUL4B, and ACSL5 in breast cancer and adjacent tissues (*p < 0.05, ***p < 0.001; two-tailed unpaired t-test). C Correlation analysis of JAB1, CUL4B, PPARG, and ACSL5 expression in a published clinical dataset (GSE72653) using a two-tailed unpaired t-test. D, E Immunohistochemical staining and analysis of JAB1 in matched tumor and adjacent normal tissues. Results are expressed as mean ± SD (**p < 0.01, ***p < 0.001; two-tailed unpaired t-test). F, G mRNA expression analysis of CUL4B or ACSL5 in normal and breast cancer tissues using published clinical datasets (GSE65194, GSE72653). Results are expressed as mean ± SD (*p < 0.05, ***p < 0.001; two-tailed unpaired t-test). H Correlation analysis between CUL4B or ACSL5 expression and survival of patients with breast cancer using a published clinical dataset (TCGA BRCA). I A proposed mechanism by which the JAB1/CUL4B complex modulates the initiation and progression of breast cancer via the PPARG/ACSL5 pathway. PTX paclitaxel, DTX docetaxel.
